Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic RNK001 NK cells plus subcutaneous interleukin-2 in AML/MDS
2019-001929-27Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of RNK001 and aldesleukin in acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts (MDS-EB) and myelodysplastic syndrome (MDS) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Dose-limiting toxicity and maximum tolerated interleukin-2 dose. Started Sep 2020; status: active.
02
Drugs
RNK001aldesleukin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts (MDS-EB)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2019-001929-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001929-27.